Intermountain Health spinout Culmination Bio secured $10 million from the venture arms of two biotech giants, CEO Lincoln Nadauld tells Axios exclusively.
Why it matters: Biotech companies rely on patient health data to produce new drugs and diagnostics, and Culmination hopes its disease-agnostic approach helps guide them to the right data faster.
